MyFinsight
Home
Blog
About
Milestone Pharmaceuticals Inc. (MIST)
Milestone Pharmaceuticals Inc. (MIST)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$98,411K
Free Cash flow
-$22,740K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Redemption of short-term investm...
Proceeds from exercise of series...
Non-cash interest expense relate...
Others
Negative Cash Flow Breakdown
Inventory
Accounts payable
Accounts receivable, net
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-09-30
2025-06-30
Accounts payable and accrued liabilities
-
-
1,273
1,213
Net loss
-28,614
19,583
-11,922
-33,727
Depreciation of property and equipment
57
-24
25
55
Amortization of debt costs
118
-200
109
208
Accretion of investment discount
-
-
0
-81
Non-cash interest expense related to senior secured convertible note
897
-1,653
859
1,678
Non-cash interest expense related to royalty financing obligation
3,705
3,133
-
-
Share-based compensation expense
1,338
-2,627
1,250
2,659
Accounts receivable, net
1,115
1,605
-
-
License receivable
-1,546
-
-
-
Other receivables
-699
569
-224
-566
Research and development tax credits receivable
90
202
-271
178
Prepaid expenses
-175
-1,332
1,829
-1,092
Inventory
2,896
1,178
-
-
Operating lease assets and liabilities
-11
-2
-8
-3
Accounts payable
-1,569
4,378
-
-
Accrued liabilities
2,428
1,836
-
-
Deferred revenue
618
416
-
-
Net cash used in operating activities
-22,714
20,213
-9,748
-26,518
Acquisition of property and equipment
26
26
2
17
Acquisition of short-term investments
-18
44,081
34,982
922
Redemption of short-term investments
156,466
-
0
-44,466
Net cash provided by investing activities
111,992
-88,573
-34,984
43,527
Proceeds from exercise of options
-130
-
122
36
Proceeds from royalty financing arrangement
0
75,000
-
-
Proceeds from issuance of common shares, net of issuance costs
0
-12,253
23,143
-
Proceeds from issuance of pre-funded warrants, net of issuance costs
-
-
-2,573
-
Proceeds from issuance of common stock warrants, net of issuance costs-Seriesa Common Warrants
-
-
9,504
-
Proceeds from issuance of common stock warrants, net of issuance costs-Seriesb Common Warrants
-
-
13,416
-
Proceeds from exercise of series a warrants, net of issuance costs
9,116
8,291
-
-
Proceeds from employee stock purchase plan
0
-116
160
140
Payment of property and equipment financing
11
11
-
-
Cash provided by financing activities
9,133
45,260
48,918
176
Net increase in cash and cash equivalents
98,411
-23,100
4,186
17,185
Cash and cash equivalents - beginning of period
46,685
46,685
25,314
-
Cash and cash equivalents - end of period
169,728
71,317
46,685
-
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Redemption of short-term
investments
$156,466K
(451.88%↑ Y/Y)
Proceeds from exercise of
series a warrants, net...
$9,116K
Acquisition of short-term
investments
-$18K
(-101.95%↓ Y/Y)
Net cash provided by
investing activities
$111,992K
(157.29%↑ Y/Y)
Cash provided by
financing activities
$9,133K
(5089.20%↑ Y/Y)
Canceled cashflow
$44,492K
Net increase in cash
and cash...
$98,411K
(472.66%↑ Y/Y)
Canceled cashflow
$22,714K
something is missing
-$44,466K
Acquisition of property and
equipment
$26K
(52.94%↑ Y/Y)
Non-cash interest
expense related to...
$3,705K
Accrued liabilities
$2,428K
License receivable
-$1,546K
Share-based compensation
expense
$1,338K
(-49.68%↓ Y/Y)
Non-cash interest
expense related to...
$897K
(-46.54%↓ Y/Y)
Other receivables
-$699K
(-23.50%↓ Y/Y)
Deferred revenue
$618K
Prepaid expenses
-$175K
(83.97%↑ Y/Y)
Amortization of debt costs
$118K
(-43.27%↓ Y/Y)
Depreciation of property and
equipment
$57K
(3.64%↑ Y/Y)
Net cash used in
operating activities
-$22,714K
(14.34%↑ Y/Y)
Canceled cashflow
$11,581K
Net loss
-$28,614K
(15.16%↑ Y/Y)
Inventory
$2,896K
Accounts payable
-$1,569K
Accounts receivable, net
$1,115K
Research and development
tax credits...
$90K
(-49.44%↓ Y/Y)
Operating lease assets and
liabilities
-$11K
(-266.67%↓ Y/Y)
Buy us a coffee